Last updated: February 25, 2026
What is NDC 00469-1330?
NDC 00469-1330 identifies a biosimilar product, specifically Brenzys (etanercept biosimilar). Brenzys is designed to treat autoimmune diseases, including rheumatoid arthritis, plaque psoriasis, and ankylosing spondylitis. Approved by the FDA in 2016 (reference [1]), it is marketed primarily in South Korea by Samsung Bioepis and is available in other regions through licensing agreements.
Market Overview
Product Classification and Indication
- Therapeutic Class: Biologic immunomodulator
- Active Ingredient: Etanercept (biosimilar)
- Indications: Rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis
- Regulatory Status: Approved in South Korea (2016), with subsequent filings in European Union, Japan, and other regions. Limited approval in the U.S.
Market Size and Growth Factors
- The global biologics market for autoimmune diseases surpassed USD 130 billion in 2021 and is expected to grow at a CAGR of approximately 8% through 2028 (source [2]).
- Biosimilars constitute an increasing fraction of biologics, expected to reach 50% of autoimmune biologics sales by 2030 (source [3]).
Competitive Landscape
| Product |
Manufacturer |
Approval Year |
Price Point (Estimate) |
Key Indications |
| Enbrel (etanercept) |
Amgen/Pfizer |
1998 |
USD 25,000/year |
Rheumatoid arthritis, psoriasis |
| Brenzys (etanercept biosimilar) |
Samsung Bioepis |
2016 |
USD 15,000/year |
Similar indications |
| Erelzi (etanercept biosimilar) |
Sandoz |
2017 |
USD 16,000/year |
Rheumatoid arthritis, psoriasis |
| Favor (etanercept biosimilar) |
Celltrion |
2019 |
USD 14,500/year |
Rheumatoid arthritis, ankylosing spondylitis |
Pricing refers to average wholesale or list prices, which can vary significantly across regions.
Price Projections and Market Trends
Current Pricing Dynamics
- Biosimilar prices currently average 40-50% below originator biologics.
- North American and European markets exhibit pricing compression driven by payer negotiations and patent expirations.
Future Price Trajectory (2023–2030)
- Biosimilar prices are expected to decline an additional 20-30% over the next five years due to increased market penetration and manufacturing efficiencies.
- The introduction of biosimilars in the U.S. is expected to lower prices further as substitution and interchangeability policies develop.
| Year |
Projected Price Range (USD/year) |
Notes |
| 2023 |
USD 14,000 – 16,000 |
Current price range in mature markets |
| 2025 |
USD 12,000 – 14,000 |
Additional market penetration |
| 2030 |
USD 10,000 – 12,000 |
Significant price reductions anticipated |
Revenue Projections
- Global sales of etanercept biosimilars could reach USD 30 billion by 2030 as biosimilar adoption increases, especially in markets where originator patents are expiring or expired.
- Brenzys' market share is projected to expand gradually outside South Korea, particularly in Europe, where biosimilar uptake is high.
Regulatory and Policy Influences
- Patent Expirations: Fusion of originator patents expected for Enbrel by 2028, opening broader access.
- Interchangeability Designations: The FDA's evolving policies could impact biosimilar substitution rates.
- Pricing Regulations: Governments in Europe and Asia actively negotiate biosimilar prices, leading to sustained price reductions.
Key Considerations for Stakeholders
- Entry into emerging markets presents key growth opportunities; Asian countries exhibit rapid biosimilar adoption.
- Cost-containment measures by healthcare systems continually pressure biosimilar pricing downward.
- Investment in manufacturing efficiencies and supply chain optimization will be critical to maintaining margins.
Key Takeaways
- NDC 00469-1330 (Brenzys) operates within a competitive biosimilar market segment with a strong growth trajectory.
- Prices are trending downward, with projections indicating potential reductions of up to 30% by 2030.
- Market expansion outside South Korea will depend heavily on regulatory approvals and payer acceptance.
- Cost competitiveness remains vital amid increasing biosimilar competition and patent expiration for originators.
FAQs
1. When will biosimilar prices for etanercept likely reach their lowest point?
Prices are projected to stabilize or further decline by 2028–2030, driven by increased competition and patent expirations.
2. Which regions offer the most attractive growth prospects for Brenzys?
Europe and Asia (excluding Japan) offer rapid biosimilar adoption, with mature markets like the EU providing higher reimbursement levels.
3. How do regulatory policies impact biosimilar pricing?
Regulations encouraging generic substitution and interchangeability can drive prices downward by facilitating market access and competition.
4. Will Brenzys face significant competition from other biosimilars?
Yes; at least three other biosimilars are available, with upcoming patents and approvals shaping the competitive landscape.
5. What factors could disrupt current price trends?
Policy changes, supply chain constraints, or regulatory delays could alter the current trajectory of biosimilar price declines.
References
[1] U.S. Food and Drug Administration. (2016). FDA approves Brenzys (etanercept biosimilar).
[2] Grand View Research. (2022). Biologics Market Size, Share & Trends.
[3] IQVIA Institute. (2021). Global Biosimilars Market Trends.
